Table 2.
All (N=498) | Alive (N=344) | Dead (N=154) | P value | |
Age (years) | 67.4±16.1 | 64.1±16.2 | 74.3±13.4 | <0.001 |
Male | 310 (62.2%) | 206 (59.9%) | 104 (67.5%) | 0.11 |
Weight (kg) (n=294) | 80.1±21.1 | 79.6±21.2 | 81.2±20.9 | 0.557 |
BMI (n=263) | 28.3±7.0 | 27.9±6.9 | 29.2±7.1 | 0.179 |
Comorbidities | ||||
Cardiovascular disease | 319 (64.1%) | 198 (57.6%) | 121 (78.6%) | <0.001 |
Diabetes | 200 (40.2%) | 128 (37.2%) | 72 (46.8%) | 0.048 |
Hypertension | 266 (53.4%) | 161 (46.8%) | 105 (68.2%) | 0.001 |
Dyslipidaemia | 158 (31.7%) | 100 (29.1%) | 58 (37.7%) | 0.061 |
COPD | 34 (6.8%) | 20 (5.8%) | 14 (9.1%) | 0.183 |
Asthma | 45 (9.0%) | 32 (9.3%) | 13 (8.4%) | 0.866 |
Chronic kidney disease | 98 (19.7%) | 56 (16.3%) | 42 (27.3%) | 0.05 |
ESRF on dialysis | 37 (7.4%) | 21 (6.1%) | 16 (10.4%) | 0.099 |
Coronary artery disease | 69 (13.9%) | 40 (11.6%) | 29 (18.8%) | 0.036 |
Previous MI | 45 (9.0%) | 25 (7.3%) | 20 (13.0%) | 0.044 |
Previous CABG | 11 (2.2%) | 6 (1.7%) | 5 (3.2%) | 0.328 |
Atrial fibrillation | 65 (13.1%) | 42 (12.2%) | 23 (14.9%) | 0.393 |
Previous PCI | 27 (5.4%) | 15 (4.4%) | 12 (7.8%) | 0.135 |
Previous CVA | 59 (11.8%) | 36 (10.5%) | 23 (14.9%) | 0.177 |
Medications | ||||
ACEi | 100 (20.1%) | 59 (17.2%) | 41 (26.6%) | 0.021 |
ARB | 52 (10.4%) | 39 (11.3%) | 13 (8.4%) | 0.428 |
NSAIDs | 10 (2.0%) | 6 (1.7%) | 4 (2.6%) | 0.507 |
Observations on admission | ||||
Heart rate | 96.2±38.7 | 96.0±44.3 | 96.6±21.5 | 0.87 |
Mean arterial pressure | 95.6±16.8 | 95.5±15.3 | 96.0±19.7 | 0.781 |
Respiratory rate | 24.6±9.7 | 24.0±8.8 | 25.9±11.3 | 0.035 |
Oxygen saturations | 94(88–96) | 94(89–96) | 91(87–96) | 0.019 |
ACEi, ACE inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; CVD, cardio-vascular disease; ESRF, end-stage renal failure; MI, Myocardial infarction; NSAID, non-steroidal anti-inflammatory drug; PCI, percutaneous coronary intervention.